Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06188065

Eosinopenia in Severe COPD Exacerbation

Eosinopenia in Severe COPD Exacerbation — Recruiting • Respiratory / COPD / Asthma • NCT06188065.

📅 14 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06188065
Sponsor
Northumbria Healthcare NHS Foundation Trust
Start
2024-01-22
ClinicaliQ Trial Snapshot
  • Eosinopenia in Severe COPD Exacerbation — Recruiting • Respiratory / COPD / Asthma • NCT06188065.
  • Sponsor: Northumbria Healthcare NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia. The main aims of the study are to: 1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to…

Eligibility Snapshot
  • : * Admitted to hospital with primary clinical diagnosis of exacerbation of COPD* * Smoking history of at least 10 pack years * Airflow obstruction: FEV1/FVC ratio < 0.7 confirmed on historic or inpatient spirometry * Capacity to give informed consent to participate

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2023 ERS/ATS Guidelines on COPD Exacerbations
Respiratory / COPD / Asthma · 30 Mar 2026
Covers diagnosis and assessment of COPD exacerbations including severity grading • Provides recommendations for pharmacologic management (bronchodilators, steroids, antibiotics) • Addresses indications…
View guideline →
Guideline
Mepolizumab for Treating Severe Refractory Eosinophilic Asthma (NICE TA431)
Respiratory / COPD / Asthma · 27 Mar 2026
Initiate mepolizumab 100 mg subcutaneously once monthly only in adults with severe eosinophilic asthma inadequately controlled on high-dose inhaled corticosteroids plus long-acting…
View guideline →
Drug Science
IL-5 Pathway — Severe Eosinophilic Asthma
Respiratory / COPD / Asthma · 04 Apr 2026
IL-5 Pathway — Severe Eosinophilic Asthma is a clinically relevant Drug Science explainer. Interleukin-5 (IL-5) is the principal cytokine governing eosinophil biology…
Explore mechanism →
Drug Science
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma
Respiratory / COPD / Asthma · 04 Apr 2026
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma is a clinically relevant Drug Science explainer. Bronchodilation in obstructive airway disease is achieved through…
Explore mechanism →
Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Guideline
GOLD 2025 Report: Global Strategy for Prevention, Diagnosis and Management of COPD
Respiratory / COPD / Asthma · 31 Mar 2026
GOLD 2025 updates COPD diagnosis criteria: spirometry FEV1/FVC
View guideline →